Glutaric Acid

If you or someone in your family carries a rare inherited problem breaking down certain proteins, this is the molecule your body leaks into urine as evidence. Glutaric acid is mainly a signal of a small group of inherited metabolic disorders, and catching them early can change the course of a child's neurological development.

This test is a research and confirmatory marker, not a wellness screen for healthy adults. It earns its place when there is a family history of glutaric aciduria, suggestive symptoms in a child, or unexplained findings on a metabolic workup.

What This Marker Actually Reflects

Glutaric acid is a small organic acid produced inside your cells' energy compartments (called mitochondria) when the body breaks down the amino acids lysine, hydroxylysine, and tryptophan. When an enzyme called glutaryl-CoA dehydrogenase is missing or weak, this breakdown gets stuck, and glutaric acid builds up in body fluids and tissues, especially the brain. The kidneys then flush some of it into urine, where this test picks it up.

Because the molecule is a downstream waste product, the level in your urine reflects how much your body is unable to process. In someone with glutaric aciduria type I (GA1), the inherited form most often linked to this marker, the result can be strikingly high. In someone without that condition, it usually sits at very low background levels.

Glutaric Aciduria Type I

GA1 is the disease this test was built to detect. It is a cerebral organic aciduria, meaning the toxic buildup hits the brain hardest. Without early treatment, infants with GA1 are at risk of acute encephalopathic crises, with the typical vulnerable window running from about three months to three years of age and rare crises reported up to age six. These crises can cause damage to a deep brain region (the striatum) and trigger a severe movement disorder with abnormal muscle contractions (dystonia).

Patients with GA1 fall into two biochemical groups: high excretors and low excretors. Both groups carry the same enzyme defect, though they differ in residual enzyme activity, and they excrete the marker at very different intensities. A low excretor result can overlap with the healthy range.

A national prospective follow-up study of 107 individuals with GA1 found that being a high excretor was the major risk factor for cognitive impairment, more important than striatal damage on imaging. This is why the biochemical pattern, not just the diagnosis, matters.

Glutaric Aciduria Type II and Type III

Two other inherited disorders also raise urinary glutaric acid. Type II, also called multiple acyl-CoA dehydrogenase deficiency, comes from defects in how cells transfer electrons during fat and amino acid breakdown. It typically appears in newborns with severe metabolic acidosis, low blood sugar, floppy muscle tone, an enlarged liver, and a Reye-like illness. Urine shows glutaric acid alongside other dicarboxylic acids and characteristic acylglycines.

Type III is rarer and milder. It is now known to be caused by mutations in the SUGCT gene (also called C7orf10), which were identified in 2008 and code for a mitochondrial enzyme called succinyl-CoA:glutarate-CoA transferase. Earlier reports framed it as a peroxisomal defect, but that hypothesis has been superseded. Type III produces very high glutaric acid in urine without obvious clinical disease in most reported cases, and clinicians debate whether it qualifies as a true disease at all.

Why a Single Reading Can Fool You

Glutaric acid in urine is a useful marker, but it is not foolproof. Several real-world factors can shift the result enough to mislead interpretation.

• Low excretor phenotype: some people with confirmed GA1 have normal or only slightly elevated urinary glutaric acid. A reassuring number does not rule out the disease when clinical suspicion is high.
• Gut bacteria: a case report described glutaric aciduria that disappeared after antibiotic treatment, meaning microbes in the gut can sometimes produce glutaric acid that ends up in urine.
• Renal function: newborns with kidney insufficiency can show falsely positive glutaric acid screening results that mimic GA1, as documented in a study of more than 170,000 infants in which 11 false positives were traced to renal insufficiency.
• Lab method differences: qualitative organic acid analysis varies between laboratories, and external quality programs have shown that some metabolic disorders, including type II glutaric aciduria, are missed by less experienced labs.

How It Compares to Related Tests

Urinary glutaric acid alone has a notable weakness: in low excretors with GA1, the level can overlap with healthy people, even after lab processing called hydrolysis. This is where companion markers earn their keep.

A stable-isotope dilution assay measuring urinary 3-hydroxyglutaric acid achieved high diagnostic sensitivity and specificity for GA1, including in low excretors whose glutaric acid overlapped with controls. In other words, 3-hydroxyglutaric acid catches the cases that plain glutaric acid misses. Newborn bloodspot screening uses a different marker called glutarylcarnitine (C5DC) to flag GA1, and a digital-tier screening strategy applied across more than 102,000 newborns reduced false positives substantially. For ambiguous cases, enzyme activity testing and GCDH gene sequencing settle the question.

Reconciling the Counterintuitive Findings

Here is the paradox at the heart of this test. Higher glutaric acid in urine generally signals a bigger metabolic block, and high excretors with GA1 do face greater risk of cognitive impairment. Yet a low or even normal urinary value does not mean low risk, because low excretors have the same enzyme defect and the same potential for brain injury if untreated. This is not a simple good-number, bad-number marker. It is a phenotype indicator, and the meaning of the number depends entirely on whether GA1 is present at all. The decision pathway, not the absolute value, drives action.

Why Trending Matters More Than a Single Reading

For someone already diagnosed with GA1 or a related disorder, serial urine organic acid testing is a way to track whether dietary treatment is keeping the metabolic block under control. Levels can vary day to day with protein intake, illness, and gut bacteria, which is why a single value at one timepoint tells only part of the story.

A reasonable cadence depends on the clinical context. For confirmed GA1 on dietary therapy, urine organic acids are typically checked at metabolic clinic visits along with growth, plasma amino acids, and acylcarnitine panels. For someone investigating an ambiguous newborn screen or family history, a baseline plus a confirmatory repeat by a metabolic specialty lab is the standard pattern. A single result outside a specialized clinical pathway should not be the basis for ruling GA1 in or out.

What an Unexpected Result Should Make You Do

If urinary glutaric acid comes back elevated outside of a known diagnosis, the next step is not panic but a structured workup. The single most informative companion test is urinary 3-hydroxyglutaric acid measured by a quantitative stable-isotope method, because its near-perfect performance for GA1 resolves most ambiguity.

From there, the decision pathway looks like this. Confirm with a plasma acylcarnitine profile checking for elevated glutarylcarnitine (C5DC). Order GCDH gene sequencing to identify the underlying mutation, which is especially important when biochemistry is borderline. Refer to a metabolic geneticist or a center experienced with organic acidurias, since interpretation in low excretors and atypical cases requires specialty judgment. For families with a known case, biological relatives should be offered targeted testing and genetic counseling. If type II is suspected, additional markers like ethylmalonate, medium-chain dicarboxylic acids, and acylglycines round out the picture.